Ruxolitinib

SUSPENDED · PHASE1 · Hematopoietic and Lymphatic System Neoplasm

Safety Issues

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.